Elevated total plasma homocysteine is an independent risk factor in the development of vascular disease in humans. Cystathionine ␤-synthase (CBS) is an enzyme that condenses homocysteine with serine to form cystathionine. In this article, we describe the effects of modulating CBS activity using a transgenic mouse that contains the human CBS cDNA under control of the zinc-inducible metallothionein promoter (Tg-CBS). In the presence of zinc, Tg-CBS mice have a 2-to 4-fold increase in liver and kidney CBS activity compared with nontransgenic littermates. Transgenic mice on standard mouse chow had a 45% decrease in their serum homocysteine (12.1 to 7.2 mol/L; PϽ0.0001) when zinc was added to drinking water, although zinc had minimal effect on their nontransgenic siblings (13.2 mol/L versus 13.0 mol/L; PϭNS). Tg-CBS mice maintained on a high-methionine, low-folate diet also had significantly lower serum homocysteine compared with control animals (179 mol/L versus 242 mol/L; PϽ0.02). CBS overexpression also significantly lowered serum cysteinylglycine (3.6 versus 2.8 mol/L; PϽ0.003) levels and reduced the levels of many amino acids in the liver. We also found that expression of Tg-CBS rescued the severe hyperhomocysteinemia and neonatal lethality of Cbs deletion animals. Our results show that elevating CBS activity is an effective method to lower plasma homocysteine levels. In addition, the creation of an inducible mouse system to modulate plasma homocysteine will also be useful in the study of homocysteine-related vascular disease.
I n the past decade, elevated plasma total homocysteine (tHcy) has emerged as an important risk factor for the development of vascular disease. More than 80 clinical and epidemiological studies, including more than 10 000 patients, have established tHcy as a risk factor for disease of the coronary, cerebral, and peripheral arteries, and for arterial and venous thromboembolism. 1 Elevated tHcy is a graded risk factor with no threshold and is independent of other known risk factors. 2 Analysis of prospective studies suggests that elevated tHcy accounts for a significant fraction of coronary artery disease and stroke in the general population. [3] [4] [5] Emerging evidence indicates that elevated tHcy is not simply a marker for vascular disease, but actually has pathological effects on vascular endothelium. Monkeys and mice with elevated tHcy levels caused by diet or mutations have impaired vascular endothelium characterized by abnormal vasodilator properties. 6, 7 Elevated tHcy has also been shown to cause oxidative stress by inhibition of NO, resulting in lower intracellular glutathione (GSH) pools in endothelial cells. 8 Finally, elevated homocysteine in both cell culture and in livers has been shown to stimulate the unfolded protein response, leading to activation and dysregulation of the sterol response pathway and apoptosis in vascular endothelium. 9, 10 Because of the link between tHcy and vascular disease, there has been much interest in strategies to lower tHcy.
Several studies have shown that folic acid and multivitamin supplementation can lower plasma homocysteine. 11, 12 In fact, as a result of the fortification of grain with folic acid in the United States, there has been a 50% decrease in the number of individuals with elevated tHcy concentrations (Ͼ13 mol/L) in the general population. 13 However, not all individuals respond to vitamin therapy. In a study of 304 individuals, it was found that 20% actually had elevations in plasma homocysteine levels after 3 weeks of folic acid supplementation, 14 which correlated with the status of singlenucleotide polymorphisms in the cystathionine ␤-synthase (Cbs) gene. 15 It has also been observed that end-stage renal disease patients as a group have extremely elevated plasma homocysteine despite vitamin therapy. 16 Thus, there is a need for additional strategies to lower plasma homocysteine.
Homocysteine has 2 possible metabolic fates: remethylation to form methionine or transsulfuration to form cystathionine ( Figure 1 ). The transsulfuration reaction is performed by the enzyme cystathionine ␤-synthase (CBS). This enzyme condenses homocysteine with serine to form cystathionine and requires pyridoxine (vitamin B 6 ) as a cofactor. Previous work has shown that it is possible to increase the activity of human CBS (hCBS) by deletion or mutation of the C-terminal regulatory domain. [17] [18] [19] These findings suggest that it may be possible to identify drugs that bind to the C-terminal domain and increase CBS activity.
The rationale for pursuing drugs that activate CBS would be enhanced by showing that elevated CBS activity can result in a lowering of plasma homocysteine in vivo. To address this question, we have created a transgenic mouse model that overexpresses CBS in an inducible manner. Our results show that CBS overexpression can lower plasma homocysteine levels in mammals.
Materials and Methods

Hemagglutinin-Tagged hCBS
A hemagglutinin (HA) epitope tagged version of hCBS was created as follows. Primers HA CBS (5Ј-ATGTACCCATACGATGTTCC-AGATTACGCTCCTTCTGAGACCCCC-3Ј) and WK90 (5Ј-TTACCAATCACGCGTGTGTTTAGGGC-3Ј) were used to polymerase chain reaction (PCR)-amplify hCBS using pHCBS 20 as template. The resulting PCR product contains the HA epitope (YPYDVPDYA) fused in frame to the second amino acid of hCBS. The PCR product was then cloned into PCR-cloning vector PCR 2.1 (Invitrogen) to create pCR2.1::hCBS. To test the epitope-tagged version of the protein for function, pCR2.1::hCBS was digested with EcoR1 and cloned into the EcoRI site pYEPXB. 20 This plasmid was then introduced in yeast-lacking endogenous CBS and tested for function by examining growth on media lacking cysteine as previously described. 20
Transgene Construct
The parent plasmid was MT-LCR expression vector 2999 obtained from Richard Palmiter 21 (University of Washington, Seattle). This vector contains 814 bp of the mouse MT-I (mMT-I) promoter fused via an NruI linker to 650 bp of the human growth hormone (hGH) 3Ј untranslated region and polyadenylation signal on an EcoRI cassette. Flanking this cassette are 10 kb of the mMT-I 5Ј hypersensitive site and 7 kb of the 3Ј hypersensitive site. Unique SalI sites flank the mouse sequences and can be used to remove the Bluescript-based vector sequences.
Because we had difficulties cloning directly into the NruI site on this large plasmid, we used the following strategy. We digested 2999 with EcoRI and isolated a 1.4-kb fragment containing 814 bp of the MT-I promoter, the NruI cloning site, and 650 bp of the hGH 3Ј untranslated region. This fragment was then inserted into the EcoRI site of pUC18. To make cloning easier, we modified the plasmid by converting the NruI site to MfeI by inserting a linker (GCAATTGC). The resultant plasmid was dubbed pUC:MT-I:MfeI. PCR2.1::hCBS was digested with EcoRI and the hCBS fragment was then cloned into the MfeI site of pUC:MT-I:MfeI, creating pLW1. To create a better translation initiation environment, pLW1 was further modified by site-directed mutagenesis to convert the Ϫ3 position nucleotide from C to A, creating pLW2. PLW2 was then digested with EcoRI, and this fragment was then cloned into 2999 digested with EcoRI to create pLW3.
Production and Screening of Transgenic Mice
PLW3 was digested with SalI, to drop out bacterial vector sequences, and the mouse-human sequences were isolated using Qiax II Gel Extraction Kit (Qiagen). The recovered DNA was then further purified by extraction 3ϫ with phenol/chloroform and ethanol precipitation. DNA was resuspended in 10 mmol/L Tris, 0.1 mmol/L EDTA, pH 7.3, at 20 ng/mL.
The purified transgene DNA fragment was microinjected into pronuclei of day 0.5 C57B6/C3H F2 embryos from C57B6/C3H F1ϫC57B6C3H F1 matings. Injected embryos were implanted into the oviducts of day 0.5 pseudopregnant female Swiss Webster mice. Tails from the resulting pups were clipped 2 weeks after birth for genotype analysis. Presence of the transgene was confirmed by PCR amplification with primers 5ЈAAGAGTTCGGCCTCAAGTGTGAG3Ј and 5ЈATGTAGTTCCGCA-CTGAGTCGGGCAGAATG3Ј, which amplify an 858-bp fragment of human CBS. DNA-positive founders were then crossed to C57B6 animals, and these pups were analyzed for germline transmission of the transgene and were tested for transgene expression as described in Figure 2 .
B6.129P2-Cbs tm1Unc mice were obtained from the Jackson Laboratory (Bar Harbor, ME). Genotyping for the Cbs tm1Unc allele was performed using a 3 primer PCR system developed by the Loscalzo Laboratory. The primers used were 5ЈGGTCTGGAATTCACTAT-GTAGC3Ј (forward primer, intron 2), 5ЈCGGATGACCTGCAT-TCATCT3Ј (reverse primer, intron2), and 5ЈGAGGTCGACGG-TATCGATA3Ј (reverse primer, neo linker). The wild-type allele gives a 300-bp product, whereas the deletion allele gives a 176-bp band product.
Mouse Diets
Mice were fed either the Fox Chase Cancer Center animal facility standard rodent chow (LabDiet 5013) or a special high-methionine, low-folate diet from Harlan Teklad (TD98272) for hyperhomocysteinemia-inducing experiments. This diet contains 5ϫ more methionine (20 g/kg versus 4.1 g/kg) and three-quarters the amount of folate (1.5 mg/kg versus 2.0 mg/kg) per kilogram compared with the standard rodent chow. For transgene induction, ZnSO 4 was added to the water at a concentration of 25 mmol/L.
Immunoblot, Enzyme Analysis, and Amino Acid Analysis of Liver
Mice were euthanized with CO 2 , and livers and kidney were harvested and immediately put on ice. The liver was homogenized using a dounce homogenizer in extract buffer [50 mmol/L Tris-HCl, pH 7.8, 25 mmol/L NaCl], to which a protease inhibitor pill (Complete-Mini, Roche) was added. Extracts were then centrifuged at 12 000g at 4°C and the supernatant was retained. Protein concentration was determined by the coomassie blue protein assay reagent (Pierce) using BSA as a standard. For Western blot analysis, 25 g of extract were run on precast 7% NuPage Tris-acetate sodium dodecyl sulfate gel (Invitrogen) and transferred to polyvinylidene difluoride membrane as described. 22 Samples were probed with a 1/5000 dilution of rabbit anti-hCBS serum. 17 Secondary antibody was anti-rabbit IgG coupled to horseradish peroxidase (Amersham). The antibody-antigen complex was visualized on photographic film after treatment with SuperSignal West Dura Extended Duration Substrate (Pierce).
CBS enzyme activity was measured using a Biochrom 30 amino acid analyzer to measure cystathionine formation. Reactions containing 100 g of liver extract, 100 mmol/L Na-N,N-bis(2hydroxyethyl)glycine (pH 8.6), 50 mol/L pyridoxal phosphate, 5 mmol/L serine, 200 mol/L S-adenosylmethionine, and 5 mmol/L L-homocysteine in a 50 L volume were incubated for 1 hour at 37°C. Units are expressed as nanomoles cystathionine/mg per hour.
Amino acid pools were analyzed by reducing 300 g of total liver homogenates with 12% dithiothreitol and then extracting with an equal volume of 10% sulfosalicylic acid followed by centrifugation. The supernatant was then analyzed on a Biochrom 30 amino acid analyzer. Peaks were identified and quantitated by comparing to a known standard.
Serum Thiol Determinations
Mice were bled from the eye socket in a standard Eppendorf tube and immediately put on ice. The samples were then centrifuged at 4°C at 12 000g for 5 minutes and the serum fraction was collected. A total of 25 L of serum was then analyzed for tHcy, cysteine, cysteinylglycine, and GSH levels as described previously, 23 except that the fluorescent thiol-bimane conjugates were resolved on a Luna 5 C18(2) column (4.6ϫ150 mm) (Phenomenex) using a System 1100 high-performance liquid chromatography-FD (Agilent). In the experiments described in Figure 5 , serum homocysteine was measured using a Biochrom 30 amino acid analyzer.
Statistics
Statistical analysis was done using Statistica for Macintosh (Stat-Soft). Reported significance values from t tests were all 2-sided.
Results
Transgene Characterization
We constructed a plasmid containing the human CBS cDNA driven by the mMT promoter ( Figure 1B ). The MT promoter (mMT-I) was chosen because its expression can be regulated by addition of zinc to drinking water, and it is expressed in high levels in liver and kidney, mirroring endogenous CBS expression. 24 The HA epitope tag was inserted in the N-terminus of CBS to distinguish between endogenous mouse CBS (mCBS) and the hCBS proteins. Our construct also contained the 5Ј and 3Ј LCR of mMT-I to help minimize expression differences attributable to different sites of integration. 21 From Ϸ200 injected C57B6/C3H hybrid embryos implanted into pseudopregnant females, we obtained 35 offspring, of which 6 contained the human CBS transgene. Three of the 6 animals transmitted the transgene to Ϸ50% of their offspring. These 3 independent transgene lines were designated 2, 21, and 25.
Initially, we examined expression of the transgene in liver and kidney. Mice from each line were either given regular water or water containing 25 mmol/L ZnSO 4 to induce the MT-I promoter. Livers and kidneys were harvested after 10 days on ZnSO 4 , and CBS levels were examined by Western blot using anti-human CBS antiserum. As shown in Figure  2A , the human transgene is tightly regulated by zinc in both the liver and kidney in all 3 lines. In the liver, the presence of zinc results in a large increase in hCBS levels but does not affect the levels of mCBS. In the kidney, zinc induces both the transgene and the endogenous mouse gene. We confirmed that the upper band was HA-tagged hCBS by Western blot with an anti-HA antibody (data not shown). We also performed Western analysis on extracts derived from a variety of other mouse tissues, including brain, skeletal muscle, spleen, lungs, colon, stomach, and adenoids. The only tissues that expressed detectable levels of hCBS were the stomach and colon. This is consistent with previously published expression patterns of transgenes being expressed from the MT-I promoter. 21 Initially, we saw some variation in hCBS expression between sibling animals within the same line and also between lines (data not shown). However, after 2 generations of backcrossing with C57B6 animals, this variability was greatly reduced ( Figure 2B ). Thus, the initial variability was probably a result of the segregating genetic background of the hybrid crosses. After backcrossing, expression levels were very similar among the 3 different lines, suggesting that the LCRs were quite effective in controlling position effects on transcription.
We also measured CBS enzyme activity in liver and kidney extracts from transgenic (Tg)-CBS animals and nontransgenic littermates ( Table 1 ). We found that in the absence of zinc, there was no difference in CBS activity levels between transgenic and nontransgenic animals in either the liver or kidney. In the liver, the mean activity of the zinc-treated transgenic animals was 2.2-fold higher than the zinc-treated nontransgenic control animals (2472 U versus 1115; Pϭ0.016). In the kidney, there was 3.5-fold elevation in CBS activity between transgenic and nontransgenic animals (935 U versus 260; Pϭ0.007). We also confirmed that zinc elevates endogenous mouse CBS in the kidney (107 U versus 260 U; Pϭ0.002).
Effects of CBS Overexpression
We next examined how CBS overexpression affects the levels of tHcy and other thiols in transgenic and control animals. We collected serum from 16 transgenic animals and 17 nontransgenic littermates on standard mouse chow and zinc-containing water, which induces MT-controlled hCBS activity. We then shifted these animals to normal water for 2 weeks and re-bled them. Serum was analyzed for tHcy, GSH, cysteine, and cysteinyl-glycine ( Figure 3 ). The mean tHcy (ϮSEM) for the nontransgenic control animals was 13.0Ϯ1.1 mol/L for animals on normal water and 13.2Ϯ1.0 mol/L on zinc-containing water (paired t test; Pϭ0.99). For the transgenic animals, tHcy was 12Ϯ0.7 mol/L in the absence of zinc but decreased 45% when the animals were put on zinc water (7.2Ϯ0.3 mol/L; paired t test; PϽ0.000003). Comparing the tHcy levels between zinc-treated control and zinc-treated transgenic animals, there was also a highly significant difference (13.2 versus 7.2 mol/L; unpaired t test; PϽ0.0001). We did not observe any difference in the levels of serum GSH between transgenic and nontransgenic animals, although the addition of zinc to the water did lower GSH levels significantly in both control and transgenic animals. Both serum cysteine and cysteinyl-glycine levels were lower in the zinc-treated transgenic animals compared with identically treated control animals, although only in cysteinyl-glycine levels were changes statistically significant (3.6 versus 2.8 mol/L; Pϭ0.003). Addition of zinc had no effect on either serum cysteine or cysteinyl-glycine levels in control animals. These results show that CBS overexpression can significantly lower serum homocysteine. We also examined how CBS overexpression affected tHcy in mice that had abnormally elevated tHcy caused by dietary intervention. Sixteen control and 12 transgenic mice were put on mouse chow containing 5ϫ the level of methionine and 25% less folate than the standard mouse chow in the presence of zinc water. After 3 weeks on this chow, blood was collected and analyzed for tHcy, GSH, cysteine, and cysteinyl-glycine ( Figure 4 ). Total serum homocysteine was 23% lower in the CBS-overexpressing animals compared with control animals (179 versus 242 mol/L; PϽ0.02), indicating that elevated CBS activity could help alleviate homocysteine elevations caused by abnormal diet. We did not see any effect of CBS overexpression on GSH or cysteine levels, although cysteinyl-glycine was reduced in CBS-overexpressing animals compared with controls.
At the completion of this experiment, we euthanized 6 transgenic animals and 6 nontransgenic littermates and examined free amino acid pools in total liver homogenates ( Table 2) using an amino acid analyzer. The amino acids present at detectable levels were threonine, serine, asparagines, glutamine, glutamic acid, glycine, alanine, valine, homocysteine, methionine, cystathionine, isoleucine, leucine, tyrosine, phenylalanine, lysine, histidine, cysteine, ornithine, glutathionine, urea, taurine, phosphoserine, and ␣-butyric acid. Statistically significant differences were observed in the levels of phenylalanine, valine, leucine, asparagine, isoleucine, ␣-aminobutyrate, and ammonia. In all cases, the pools of these amino acids were low in the transgenic compared with the control animals. Interestingly, none of the changed amino acids were part of the methionine or cysteine metabolic pathway. This suggests that the control of amino acid homeostasis in the liver is extremely complex.
Tg-CBS Rescues Cbs tm1Unc Animals
Watanabe et al created a knockout allele for CBS (Cbs tm1Unc ) and found that animals homozygous for this allele showed severe homocysteinemia and growth retardation and rarely survived beyond 6 weeks. 25 We confirmed these findings in our own colony of Cbs tm1Unc mice. We found that at the time of genotyping (aged 4 to 6 weeks), only 2 of 258 offspring of Cbs/ Cbs tm1Unc ϫCbs/ Cbs tm1Unc mating were homozygous for Cbs tm1Unc . To determine whether our transgene could rescue these effects, we mated our Tg-CBS animals to animals Cbs/ Cbs tm1Unc and obtained Tg-CBS Cbs/ Cbs tm1Unc offspring. These animals were then put on zinc water and backcrossed to Cbs/ Cbs tm1Unc mice. Our belief was that if the transgene rescued lethality, we would expect approximately one-eighth (12.5%) of the offspring to be both homozygous for Cbs tm1Unc and hemizygous for the transgene. Furthermore, we would also expect to see significantly more viable homozygous animals with the transgene than without the transgene. Of 182 offspring born, 21 were homozygous for the knockout allele, and of these, 18 also contained the transgene (9.9% of the total). These results show that the transgene is able to rescue the lethality associated with homozygosity for Cbs tm1Unc .
We also examined tHcy levels in all 18 Tg-CBS Cbs tm1Unc / Cbs tm1Unc animals in both the presence and absence of induction by zinc. As shown in Figure 5 , tHcy was significantly elevated when mice were switched from zinc-containing to nonzinc-containing water. The mean tHcy went from 67.3 mol/L to 190.37 mol/L (Pϭ0.000015; nϭ18). Interestingly, we saw a greater effect in female animals than in male animals. In females, mean tHcy increased from 25 mol/L to 231 mol/L (Pϭ0.0000078; nϭ7), whereas in males, tHcy went from 93 mol/L to 179 mol/L (Pϭ0.0005; nϭ11). We hypothesize that the relatively high levels of tHcy observed in the presence of zinc in some animals (especially males) may be attributable to attenuation of zinc response because of the prolonged exposure to zinc. However, despite this possibility, approximately one-third of all the animals had tHcy within the normal range when on zinc and extreme elevations in tHcy when zinc was removed. In summary, our results show that using the Tg-CBS, it is possible to obtain healthy adult animals with extremely elevated tHcy.
Discussion
Despite the identification of plasma homocysteine as an independent risk factor for vascular disease and of CBS as a key enzyme in homocysteine catabolism, the in vivo feasibility of reducing tHcy by elevating CBS activity was unknown. On the basis of the enzymatic kinetics of CBS and the other enzymes in the pathway, it was unclear that CBS activity would be rate limiting for the clearance of homocysteine. The K m of CBS for homocysteine is estimated to be Ϸ5 mmol/L, whereas the K m for both methionine synthase and betaine-dependent homocysteine methyltransferase are in the low micromolar range. 26 -28 This has led to the view that CBS activity was used only in situations in which there was "homocysteine" overload, such as immediately after a methionine-loaded meal. 29 However, we observed that overexpression of CBS lowered plasma homocysteine effectively when animals were maintained on a standard diet. This suggests that even under normal dietary conditions, methionine synthase and betaine-dependent homocysteine methyltransferase are not able to convert homocysteine to methionine fast enough to prevent a substantial buildup of homocysteine to the point at which it could be used by CBS as a substrate. The fact that the percentage lowering was worse in the high methionine diet suggests that under extreme conditions, it may be possible to saturate the transsulfuration pathway such that overexpression of CBS is less effective. Our results are also consistent with work showing that children with Down Syndrome caused by a third copy of chromosome 21 have lower tHcy compared with sibling controls. 30 A priori, it might be expected that elevating CBS activity would raise the levels of other serum thiols because they all contain cysteine, which is downstream of CBS. Thus, it was somewhat surprising that neither GSH nor cysteine levels changed significantly in the transgenic animals. Even more unexpected was the fact that serum cysteinyl-glycine levels actually fell in response to elevated CBS activity. This occurred in both animals on a regular diet and on a highmethionine, low-folate diet, suggesting that this observation was not an artifact. Unlike our observation in mice, the decreased tHcy in children with Down Syndrome was accompanied by a statistically significant increase in both plasma cysteine and GSH. 30 One possible explanation is that in the mouse ␥-cystathionase, activity might be rate limiting, resulting in a lowering of homocysteine but no increase in cysteine. Another possibility is that there is some sort of negative cross-talk between the transsulfuration pathway and the ␥-glutamyl cycle.
Our analysis of liver amino acid levels indicates that there is complex homoeostasis of amino acid metabolism in mice. Although we found that CBS-overexpressing animals did have reduced levels of liver homocysteine and elevated levels of cystathionine as expected, the most significant changes were in the levels of amino acids that were not directly related to the methionine or cysteine metabolic pathways, such as leucine, isoleucine, asparagine, valine, phenylalanine, and ␣-aminobutyrate. It is not unprecedented that overexpression of a single amino acid biosynthetic pathway can have global consequences. In the yeasts Saccharomyces cerevisiae and Candida albicans starvation for a single amino acid results in the upregulation of a variety of amino acid biosynthetic genes through the action of the transcriptional activator GCN4. 31 In mammalian cells, the upregulation of the ␣-aminoisobutyric acid transport system by global amino acid starvation can be suppressed by the addition of a single amino acid to the media. 32 Our results also bear on the question of the relative importance of the liver and kidney in the control of plasma homocysteine levels. Unexpectedly, we found that the endogenous mouse CBS gene is induced in the kidney (but not in the liver) with exposure to zinc. However, from our serum homocysteine data, it is clear that nontransgenic animals did not have any difference in their plasma homocysteine levels when exposed to zinc ( Figure 3A ). This implies that the kidney is not a key player in control of plasma homocysteine levels in the mouse. If this were true as well in humans, then the hyperhomocysteinemia observed in humans with endstage renal disease may not be caused by the failure of the kidney to metabolize plasma homocysteine but may be attributable to an indirect effect on homocysteine metabolism in the liver.
Other than the above-described metabolic consequences, we did not observe any other differences between control and Tg-CBS mice. The mice exhibited normal growth, normal behavior, and had normal-looking pups. These findings indicate that elevated CBS activity in the liver is essentially benign and suggests that treatments that activate CBS activity could potentially be useful in lowering plasma homocysteine in human patients. One possibility is that gene therapy could be used to deliver either extra copies of CBS gene or CBS protein to the liver. Although in theory a powerful approach, the technical hurdles are still great. A potentially more feasible strategy would be to use small-molecule drugs that could elevate activity of existing CBS protein in the liver. We have shown previously that the C-terminal domain of CBS acts as a negative regulatory domain (ie, deletion of the C terminus results in a protein with significantly elevated CBS activity). 17 It should be possible to design or screen for drugs that bind to this domain in such a way as to cause activation of endogenous CBS. Because we were able to achieve reduction of serum homocysteine levels with a relatively modest 2.2-fold increase in CBS activity, it seems possible that such effects might be possible to achieve by targeting compounds to the regulatory domain. Such compounds could be useful in the treatment of hyperhomocysteinemia in Figure 5 . tHcy of Tg-CBS Cbs tm1Unc / Cbs tm1Unc animals with (Zn) and without (ϪZn) zinc. Tg-CBS Cbs tm1Unc / Cbs tm1Unc animals between 2 and 8 months of age on ZnSO 4 water had serum collected and were then shifted to regular water for 2 weeks, at which time serum was collected again. All of the animals were derived from founder 25. The squares connected by the filled in lines represent the male animals, whereas the circles connected by the dotted lines represent the female animals.
populations, such as end-stage renal disease patients, that are resistant to homocysteine lowering by B-complex vitamin therapy. 16 We also demonstrated that expression of human CBS can functionally complement deletion of mouse Cbs. By crossing in the transgene, we were able to obtain normal-sized, healthy-looking Cbs deletion animals that lived well into adulthood. Plasma homocysteine on these animals was somewhat elevated on average, but approximately one-third of the animals had homocysteine levels that were within the normal range. Thus, we were able to rescue the neonatal lethality defect and at least partially rescue the severe homocysteinemia with the transgene. When zinc was removed, we were able to obtain extremely elevated plasma homocysteine levels as high as that observed in the surviving Cbs homozygotes described by Watanabe et al 25 The ability to produce healthy adult animals whose tHcy levels can be modulated by zinc should be extremely useful to investigators interested in the pathophysiology of tHcy.
